Tofacitinib for Immune Skin Conditions in Down Syndrome
Recruitment Status: recruiting as of August 2020.
Estimated Completion Date: August 2024
Sponsors and Collaborators: University of Colorado, Denver and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Information provided by (Responsible Party): University of Colorado, Denver
Brief Summary: People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is safe and could improve associated skin conditions.
The study evaluates the safety and efficacy treatment with Tofacitinib, an FDA-approved drug known to block IFN signaling, in adults with DS and an autoimmune and/or autoinflammatory skin condition. Investigators will also measure the impact of interferon inhibition on a variety of molecular markers, as well as the cognitive abilities and quality of life of participants.
Please link complete details: https://clinicaltrials.gov/ct2/show/NCT04246372
Location: Aurora, Colorado
Contact: Angela Rachubinski, PhD 303-724-7366, DSresearch@ucdenver.edu
Belinda Enriquez Estrada, MS, 303-724-0491 DSresearch@ucdenver.edu
Location: Aarhus, Denmark